127 related articles for article (PubMed ID: 38530938)
1. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
Chen Z; Wang M; Wu D; Zhao L; Metwally H; Jiang W; Wang Y; Bai L; McEachern D; Luo J; Wang M; Li Q; Matvekas A; Wen B; Sun D; Chinnaiyan AM; Wang S
J Med Chem; 2024 Apr; 67(7):5351-5372. PubMed ID: 38530938
[TBL] [Abstract][Full Text] [Related]
2. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
Chen Z; Wang M; Wu D; Bai L; Xu T; Metwally H; Wang Y; McEachern D; Zhao L; Li R; Takyi-Williams J; Wang M; Wang L; Li Q; Wen B; Sun D; Wang S
J Med Chem; 2024 Apr; 67(7):5275-5304. PubMed ID: 38477974
[TBL] [Abstract][Full Text] [Related]
3. Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
Xiang W; Zhao L; Han X; Qin C; Miao B; McEachern D; Wang Y; Metwally H; Kirchhoff PD; Wang L; Matvekas A; He M; Wen B; Sun D; Wang S
J Med Chem; 2021 Sep; 64(18):13487-13509. PubMed ID: 34473519
[TBL] [Abstract][Full Text] [Related]
4. Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
Han X; Zhao L; Xiang W; Miao B; Qin C; Wang M; Xu T; McEachern D; Lu J; Wang Y; Metwally H; Yang CY; Kirchhoff PD; Wang L; Matvekas A; Takyi-Williams J; Wen B; Sun D; Ator M; Mckean R; Wang S
J Med Chem; 2023 Jul; 66(13):8822-8843. PubMed ID: 37382562
[TBL] [Abstract][Full Text] [Related]
5. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.
Han X; Wang C; Qin C; Xiang W; Fernandez-Salas E; Yang CY; Wang M; Zhao L; Xu T; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
J Med Chem; 2019 Jan; 62(2):941-964. PubMed ID: 30629437
[TBL] [Abstract][Full Text] [Related]
6. Discovery of
Zhang B; Liu C; Yang Z; Zhang S; Hu X; Li B; Mao M; Wang X; Li Z; Ma S; Zhang S; Qin C
J Med Chem; 2023 Aug; 66(16):11158-11186. PubMed ID: 37556600
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins.
Thomas JE; Wang M; Jiang W; Wang M; Wang L; Wen B; Sun D; Wang S
J Med Chem; 2023 Jun; 66(12):8178-8199. PubMed ID: 37276143
[TBL] [Abstract][Full Text] [Related]
8. Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti J; Sharp A; Brooks N; Yuan W; McNair C; Chand SN; Pal A; Figueiredo I; Riisnaes R; Gurel B; Rekowski J; Bogdan D; West W; Young B; Raja M; Prosser A; Lane J; Thomson S; Worthington J; Onions S; Shannon J; Paoletta S; Brown R; Smyth D; Harbottle GW; Gil VS; Miranda S; Crespo M; Ferreira A; Pereira R; Tunariu N; Carreira S; Neeb AJ; Ning J; Swain A; Taddei D; ; Schiewer MJ; Knudsen KE; Pegg N; de Bono JS
Cancer Discov; 2021 May; 11(5):1118-1137. PubMed ID: 33431496
[TBL] [Abstract][Full Text] [Related]
9. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.
Han X; Zhao L; Xiang W; Qin C; Miao B; McEachern D; Wang Y; Metwally H; Wang L; Matvekas A; Wen B; Sun D; Wang S
J Med Chem; 2021 Sep; 64(17):12831-12854. PubMed ID: 34431670
[TBL] [Abstract][Full Text] [Related]
10. p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
Luo J; Chen Z; Qiao Y; Ching-Yi Tien J; Young E; Mannan R; Mahapatra S; He T; Eyunni S; Zhang Y; Zheng Y; Su F; Cao X; Wang R; Cheng Y; Seri R; George J; Shahine M; Miner SJ; Vaishampayan U; Wang M; Wang S; Parolia A; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38586029
[TBL] [Abstract][Full Text] [Related]
11. Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.
Xiang W; Zhao L; Han X; Xu T; Kregel S; Wang M; Miao B; Qin C; Wang M; McEachern D; Lu J; Bai L; Yang CY; Kirchhoff PD; Takyi-Williams J; Wang L; Wen B; Sun D; Ator M; Mckean R; Chinnaiyan AM; Wang S
J Med Chem; 2023 Sep; 66(18):13280-13303. PubMed ID: 37683104
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
13. Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer.
Chen L; Han L; Mao S; Xu P; Xu X; Zhao R; Wu Z; Zhong K; Yu G; Wang X
Eur J Med Chem; 2021 Apr; 216():113307. PubMed ID: 33652354
[TBL] [Abstract][Full Text] [Related]
14. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma.
Chang Q; Li J; Deng Y; Zhou R; Wang B; Wang Y; Zhang M; Huang X; Li Y
J Med Chem; 2024 Feb; 67(4):2466-2486. PubMed ID: 38316017
[TBL] [Abstract][Full Text] [Related]
16. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
Ponnusamy S; He Y; Hwang DJ; Thiyagarajan T; Houtman R; Bocharova V; Sumpter BG; Fernandez E; Johnson D; Du Z; Pfeffer LM; Getzenberg RH; McEwan IJ; Miller DD; Narayanan R
Clin Cancer Res; 2019 Nov; 25(22):6764-6780. PubMed ID: 31481513
[TBL] [Abstract][Full Text] [Related]
17. A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo.
Zhao L; Han X; Lu J; McEachern D; Wang S
Neoplasia; 2020 Oct; 22(10):522-532. PubMed ID: 32928363
[TBL] [Abstract][Full Text] [Related]
18. FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Caligiuri M; Williams GL; Castro J; Battalagine L; Wilker E; Yao L; Schiller S; Toms A; Li P; Pardo E; Graves B; Azofeifa J; Chicas A; Herbertz T; Lai M; Basken J; Wood KW; Xu Q; Guichard SM
Target Oncol; 2023 Mar; 18(2):269-285. PubMed ID: 36826464
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
Wang A; Luo X; Wang Y; Meng X; Lu Z; Yang Y
J Med Chem; 2022 Sep; 65(18):12460-12481. PubMed ID: 36070471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
